MarvelBiome — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

MarvelBiome is a private, clinical-stage biotech founded in 2019 and based in San Diego, operating in the microbiome therapeutics sector. The company is developing a platform for the rational design of bacterial consortia to create Live Biotherapeutic Products (LBPs) for various diseases. With a high-profile advisory board and a focus on translating pioneering science, MarvelBiome is positioned in a high-potential but competitive and technically challenging field. The company is currently pre-revenue and its specific pipeline details and financial backing are not publicly disclosed on its website.

Microbiome

Technology Platform

Platform for the rational design of human commensal bacterial consortia to create Live Biotherapeutic Products (LBPs).

Opportunities

The global microbiome therapeutics market represents a high-growth frontier with multi-billion dollar potential, particularly in areas of high unmet need like gastrointestinal and immune-mediated diseases.

MarvelBiome's rational design platform could enable more targeted and effective therapies than earlier empirical approaches, positioning it well for strategic partnerships or leadership in specific indications.

Risk Factors

Key risks include the high scientific and technical complexity of developing effective, manufacturable bacterial consortia, an evolving and uncertain regulatory pathway for Live Biotherapeutic Products, and intense competition in the microbiome space from better-funded or more advanced companies.

As a pre-revenue private firm, securing adequate funding to reach clinical milestones is also a persistent risk.

Competitive Landscape

The competitive landscape is crowded with well-established players like Seres Therapeutics (commercial product for C. diff), Vedanta Biosciences, and Finch Therapeutics, alongside numerous private companies and large pharma exploring the space. MarvelBiome's differentiation hinges on its 'rational design' approach, but it must demonstrate clinical proof-of-concept to establish a competitive position.

More companies in Microbiome Therapeutics →More companies in United States →